Regulatory interplay between mir-181a-5p and estrogen receptor signaling cascade in breast cancer

Research output: Contribution to journalArticle

Standard

Regulatory interplay between mir-181a-5p and estrogen receptor signaling cascade in breast cancer. / Benedetti, Rosaria; Papulino, Chiara; Sgueglia, Giulia; Chianese, Ugo; De Marchi, Tommaso; Iovino, Francesco; Rotili, Dante; Mai, Antonello; Niméus, Emma; Aversana, Carmela Dell’; Altucci, Lucia.

In: Cancers, Vol. 13, No. 3, 543, 2021.

Research output: Contribution to journalArticle

Harvard

Benedetti, R, Papulino, C, Sgueglia, G, Chianese, U, De Marchi, T, Iovino, F, Rotili, D, Mai, A, Niméus, E, Aversana, CD & Altucci, L 2021, 'Regulatory interplay between mir-181a-5p and estrogen receptor signaling cascade in breast cancer', Cancers, vol. 13, no. 3, 543. https://doi.org/10.3390/cancers13030543

APA

Benedetti, R., Papulino, C., Sgueglia, G., Chianese, U., De Marchi, T., Iovino, F., Rotili, D., Mai, A., Niméus, E., Aversana, C. D., & Altucci, L. (2021). Regulatory interplay between mir-181a-5p and estrogen receptor signaling cascade in breast cancer. Cancers, 13(3), [543]. https://doi.org/10.3390/cancers13030543

CBE

Benedetti R, Papulino C, Sgueglia G, Chianese U, De Marchi T, Iovino F, Rotili D, Mai A, Niméus E, Aversana CD, Altucci L. 2021. Regulatory interplay between mir-181a-5p and estrogen receptor signaling cascade in breast cancer. Cancers. 13(3):Article 543. https://doi.org/10.3390/cancers13030543

MLA

Vancouver

Author

Benedetti, Rosaria ; Papulino, Chiara ; Sgueglia, Giulia ; Chianese, Ugo ; De Marchi, Tommaso ; Iovino, Francesco ; Rotili, Dante ; Mai, Antonello ; Niméus, Emma ; Aversana, Carmela Dell’ ; Altucci, Lucia. / Regulatory interplay between mir-181a-5p and estrogen receptor signaling cascade in breast cancer. In: Cancers. 2021 ; Vol. 13, No. 3.

RIS

TY - JOUR

T1 - Regulatory interplay between mir-181a-5p and estrogen receptor signaling cascade in breast cancer

AU - Benedetti, Rosaria

AU - Papulino, Chiara

AU - Sgueglia, Giulia

AU - Chianese, Ugo

AU - De Marchi, Tommaso

AU - Iovino, Francesco

AU - Rotili, Dante

AU - Mai, Antonello

AU - Niméus, Emma

AU - Aversana, Carmela Dell’

AU - Altucci, Lucia

PY - 2021

Y1 - 2021

N2 - The efficacy and side effects of endocrine therapy in breast cancer (BC) depend largely on estrogen receptor alpha (ERα) expression, the specific drug administered, and treatment scheduling. Although the benefits of endocrine therapy outweigh any adverse effects in the initial stages of BC, later- or advanced-stage tumors acquire resistance to treatments. The mechanisms underlying tumor resistance to therapy are still not well understood, posing a major challenge for BC patient care. Epigenetic regulation and miRNA expression may be involved in the switch from a treatment-sensitive to a treatment-resistant state and could provide a valid therapeutic strategy for ERα negative BC. Here, a hybrid lysine-specific histone demethylase inhibitor, MC3324, displaying selective estrogen receptor down-regulator-like activities in BC, was used to highlight the interplay between epigenetic and ERα signaling. MC3324 anticancer action is mediated by microRNA (miRNA) expression regulation, indicating an innovative function for this molecule. Integrated analysis suggests a crosstalk between estrogen signaling, ERα interactors, miRNAs, and their putative targets. Specifically, miR-181a-5p expression is regulated by MC3324 and has an impact on cellular levels of ERα. A comparison of breast tumor versus healthy mammary tissues confirmed the important role of miR-181a-5p in ERα regulation and points to its putative predictive function in BC therapy.

AB - The efficacy and side effects of endocrine therapy in breast cancer (BC) depend largely on estrogen receptor alpha (ERα) expression, the specific drug administered, and treatment scheduling. Although the benefits of endocrine therapy outweigh any adverse effects in the initial stages of BC, later- or advanced-stage tumors acquire resistance to treatments. The mechanisms underlying tumor resistance to therapy are still not well understood, posing a major challenge for BC patient care. Epigenetic regulation and miRNA expression may be involved in the switch from a treatment-sensitive to a treatment-resistant state and could provide a valid therapeutic strategy for ERα negative BC. Here, a hybrid lysine-specific histone demethylase inhibitor, MC3324, displaying selective estrogen receptor down-regulator-like activities in BC, was used to highlight the interplay between epigenetic and ERα signaling. MC3324 anticancer action is mediated by microRNA (miRNA) expression regulation, indicating an innovative function for this molecule. Integrated analysis suggests a crosstalk between estrogen signaling, ERα interactors, miRNAs, and their putative targets. Specifically, miR-181a-5p expression is regulated by MC3324 and has an impact on cellular levels of ERα. A comparison of breast tumor versus healthy mammary tissues confirmed the important role of miR-181a-5p in ERα regulation and points to its putative predictive function in BC therapy.

KW - Breast cancer

KW - Endocrine therapy

KW - Epigenetic SERD

KW - ERα

KW - Hormone signaling

KW - MiR-181a-5p

U2 - 10.3390/cancers13030543

DO - 10.3390/cancers13030543

M3 - Article

C2 - 33535487

AN - SCOPUS:85100578967

VL - 13

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 3

M1 - 543

ER -